Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A, Guerrero A, Maldonado X, Álvarez A, San-Segundo CG, Rodríguez MÁC, Solé JM, Olivé AP, Casas F, Boladeras A, de Vidales CM, de la Torre MLV, Vara S, Sanz JL, Calvo FA. Zapatero A, et al. Among authors: sole jm. Lancet Oncol. 2022 May;23(5):671-681. doi: 10.1016/S1470-2045(22)00190-5. Epub 2022 Apr 12. Lancet Oncol. 2022. PMID: 35427469 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34700630
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
Zapatero A, Álvarez A, Guerrero A, Maldonado X, González San Segundo C, Cabeza MA, Martín de Vidales C, Solé JM, Pedro Olivé A, Casas F, Boladeras A, Vázquez de la Torre ML, Vara S, Calvo FA. Zapatero A, et al. Among authors: sole jm. Radiother Oncol. 2021 Jul;160:115-119. doi: 10.1016/j.radonc.2021.04.018. Epub 2021 May 5. Radiother Oncol. 2021. PMID: 33964325 Free article. Clinical Trial.
Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study.
Suárez JF, Zamora V, Garin O, Gutiérrez C, Pont À, Pardo Y, Goñi A, Mariño A, Hervás A, Herruzo I, Cabrera P, Sancho G, Ponce de León J, Macías V, Guedea F, Vigués F, Castells M, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer. Suárez JF, et al. Sci Rep. 2022 Jul 22;12(1):12589. doi: 10.1038/s41598-022-16395-w. Sci Rep. 2022. PMID: 35869124 Free PMC article.
Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
Carles J, Nogue M, Sole JM, Foro P, Domenech M, Suarez M, Gallardo E, García D, Ferrer F, Gelabert-Mas A, Gayo J, Fabregat X. Carles J, et al. Among authors: sole jm. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1085-91. doi: 10.1016/j.ijrobp.2009.03.024. Epub 2009 Jul 4. Int J Radiat Oncol Biol Phys. 2010. PMID: 19577864 Clinical Trial.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Regan MM, et al. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20. Lancet Oncol. 2011. PMID: 22018631 Free PMC article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS).
Avila M, Pardo Y, Castells M, Ferrer F, Boladeras A, Pera J, Prada PJ, Guix B, de Paula B, Hernandez H, Pont A, Alonso J, Garin O, Bremner K, Krahn M, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer. Avila M, et al. Qual Life Res. 2014 Nov;23(9):2481-7. doi: 10.1007/s11136-014-0701-0. Epub 2014 May 1. Qual Life Res. 2014. PMID: 24789667 Free article.
41 results